Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A [Phase 3]
Results from a Phase 3 safety study of subcutaneous rituximab in CD20-positive diffuse large B-cell lymphoma or CD20-positive follicular lym…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: MB-CART20.1 Lymphoma [Phase 1, Phase 2]
Miltenyi Biomedicine's MB-CART20.1 Lymphoma trial in relapsed or refractory B-cell non-Hodgkin lymphoma and non-Hodgkin lymphoma has complet…
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Clinical trial update for a lentiviral gene therapy (Zamtocabtagene Autoleucel) in non-Hodgkin lymphoma, noting ongoing recruitment.
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MBS303 in…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China [Phase 1]
Phase 1 clinical trial update evaluating Maplirpacept in advanced non-Hodgkin lymphoma or multiple myeloma in China has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-11-15Clinical Trial Update: APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) [Phase 1, Phase 2]
A Phase 1/Phase 2 trial of APR-246 in combination with acalabrutinib or venetoclax in relapsed/refractory non-Hodgkin lymphoma has been term…
-
CLINICAL_TRIALS trial_result · 2024-11-13Clinical Trial Update: A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies [Phase 1, Phase 2]
Update on the completed Phase 1/2 study of ZX-101A assessing activity, safety, and tolerability in relapsed/refractory hematological maligna…
-
CLINICAL_TRIALS trial_result · 2024-11-13Clinical Trial Update: Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies [Phase 1]
A Phase 1 clinical trial evaluating the safety and tolerability of XmAb13676 (plamotamab) in CD20-expressing hematologic malignancies has co…
-
CLINICAL_TRIALS trial_result · 2024-11-12Clinical Trial Update: Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL [Phase 1]
Phase 1 trial evaluating haploidentical stem cell transplantation with prophylactic natural killer donor lymphocyte infusion in lymphoma, mu…
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating romidepsin with lenalidomide in adults with relapsed or refractory lymphomas and multiple myeloma has completed w…
-
CLINICAL_TRIALS trial_result · 2024-10-30Clinical Trial Update: Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation [Phase 2]
Phase 2 clinical trial update on a Triplex CMV vaccine designed to prevent CMV infection in patients undergoing hematopoietic stem cell tran…
-
FDA approval · 2024-10-29FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Nexus Pharmaceuticals, LLC)
FDA approved Nexus Pharmaceuticals, LLC to market a generic cyclophosphamide product under Original Application ANDA216783.
-
CLINICAL_TRIALS trial_result · 2024-10-26Clinical Trial Update: Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies [Phase 1]
This Phase 1 trial evaluated the combination of venetoclax and selinexor in relapsed or refractory high-risk hematologic malignancies, inclu…
-
CLINICAL_TRIALS trial_result · 2024-10-24Clinical Trial Update: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 trial of bendamustine plus obinutuzumab induction with obinutuzumab maintenance in untreated mantle cell lymphoma; the study is term…
-
CLINICAL_TRIALS withdrawal · 2024-10-24Clinical Trial Update: Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas [Phase 1, Phase 2]
Clinical trial evaluating FE 203799 in adults with lymphomas has been withdrawn. The study examined safety, tolerability, and PK/PD in Phase…
-
FDA approval · 2024-10-23FDA Approved: JYLAMVO — Supplemental Application (SHORLA ONCOLOGY INC.)
The FDA approved a supplemental application for JYLAMVO (methotrexate) filed by SHORLA ONCOLOGY INC.
-
CLINICAL_TRIALS withdrawal · 2024-10-22Clinical Trial Update: (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). [Phase 1]
Phase 1 pediatric lymphoma trial evaluating pediTACTAL TAA-specific cytotoxic T-lymphocytes has been withdrawn.
-
EMA approval · 2024-10-21EMA Authorised: Zydelig (Idelalisib) — Gilead Sciences Ireland UC
EMA authorised Zydelig (idelalisib) for certain non-Hodgkin lymphoma and chronic lymphocytic leukemia.
-
CLINICAL_TRIALS trial_result · 2024-10-21Clinical Trial Update: Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) [Phase 2]
Phase 2 trial of a cytomegalovirus vaccine for donors and recipients undergoing allogeneic hematopoietic cell transplantation has completed,…
-
CLINICAL_TRIALS research · 2024-10-21Clinical Trial Update: Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ) [Phase 2]
A Phase 2 clinical trial is evaluating high-dose methotrexate in combination with thiotepa and zanubrutinib for newly diagnosed primary cent…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 study of the intravenous agent S65487 in relapsed or refractory hematologic cancers (acute myeloid leukemia, non-Hodgkin lymphoma, m…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1]
A Phase 1 dose-finding study of CC-96673 in relapsed or refractory Non-Hodgkin's lymphoma was terminated.
-
CLINICAL_TRIALS research · 2024-10-08Clinical Trial Update: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas [Phase 1]
A Phase 1 trial of CC-90010 in patients with advanced solid tumors and relapsed/refractory Non-Hodgkin's lymphomas has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-10-04Clinical Trial Update: An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Termination of a Phase 1/2 open-label trial evaluating mosunetuzumab in combination with tiragolumab, with or without atezolizumab, in B-cel…